USPTO serial 79354822
KODEGNOS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 2, 2024
- Examiner
- LEHKER, DAWN FELDMAN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with KODEGNOS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Boehringer Ingelheim International GmbH
DE
Other trademarks owned by Boehringer Ingelheim International GmbH
Boehringer Ingelheim International GmbH
DE
Other trademarks owned by Boehringer Ingelheim International GmbH
Boehringer Ingelheim International GmbH
DE
Other trademarks owned by Boehringer Ingelheim International GmbH
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the prevention and treatment of diseases and disorders of the alimentary tract and metabolism; pharmaceutical preparations for the prevention and treatment of diseases and disorders and of the blood and blood forming organs; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system; pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, damaged skin and tissues; pharmaceutical preparations for the prevention and treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the prevention and treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment and prevention of hormonal diseases and disorders; pharmaceutical preparations for the treatment and prevention of infectious diseases and disorders and viral infections; pharmaceutical preparations for the prevention and treatment of oncological and auto-immune diseases and disorders; pharmaceutical preparations, namely, cell based immune therapeutics for treatment of cancer, for treatment of immunological diseases, and treatment of infectious diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Boehringer Ingelheim International GmbH
- Other trademarks owned by Boehringer Ingelheim International GmbH
- Other trademarks owned by Boehringer Ingelheim International GmbH
- Other trademarks in Class 005
- Similar marks named KODEGNOS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 30, 2024 | FINV | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 8, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 8, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 2, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 2, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 2, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 17, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Oct 17, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 17, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 27, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 27, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Sep 27, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 15, 2023 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Aug 2, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 1, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 31, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 31, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 21, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 28, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 28, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 20, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 31, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 30, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 30, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 22, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 18, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 17, 2022 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Nov 10, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |